Clinical Trial Goal
To find out:
- The highest dose of linvoseltamab that's safe to give
- If linvoseltamab is safe and works well to treat multiple myeloma that has not yet been treated
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has not yet been treated
- Have only been treated with 2 of the following (your doctor can tell you this):
- Anti-CD38
- Immunomodulatory drug (IMiD)
- Proteosome inhibitor (PI)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Linvoseltamab is a bispecific antibody that targets BCMA on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Linvoseltamab – Given as intravenous (IV) infusions up to 4 times
You may continue treatment for up to 6 months. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for 2 years.
The Food and Drug Administration (FDA) has approved linvoseltamab to treat multiple myeloma that has come back (relapsed) or not gotten better with treatment (refractory). Using it in this way to treat newly diagnosed multiple myeloma is new and unproven.
Locations
University of MiamiRECRUITING
Miami, Florida
Dickran Kazandjian, MD, 305-243-5001, dkazandjian@miami.edu
Sponsors
collaborator: Regeneron Pharmaceuticals, lead: Dickran Kazandjian, MD
